Sign inJoin waitlistJoin the waitlist

Richard Drachtman

Clinical Section Chief, Division of Pediatric Hematology/Oncology · Rutgers Health

Credentials: · · ·

History

Division of Pediatric Hematology/Oncology Section · Rutgers Health
Present
Rutgers Health
Present

Pediatric Hematology-Oncology
Mount Sinai Health System
1987–1988
North Shore University Hospital - Northwell Health
1984–1987
CHICAGO COLL OF MED AND SURG
1980–1984

Research

Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity
Pediatric Hematology and Oncology · 2002 · First of 7 authors · Corresponding · 105 citations
Stroke risk in siblings with sickle cell anemia
Blood · 2003 · 78 citations
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre…
The Lancet Oncology · 2018 · 76 citations

Peter Cole
15 papers
Kara Kelly
9 papers
LE
Lawrence Ettinger
7 papers
BA
Blanche Alter
6 papers
Brad Hoppe
6 papers · 1 as a fellow
KM
Kathleen Mccarten
6 papers
Rahul Parikh
6 papers
Archana Sharma
5 papers
Margaret Masterson
5 papers
BK
Barton Kamen
4 papers
Beth Savage
4 papers
Cindy Schwartz
4 papers

Clinical trials

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Site PI · Recruiting · Phase 2
Novartis Pharmaceuticals
2026–2033
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2025–2031
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2031
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Site PI · Recruiting · Phase 1, Phase 2
PedAL BCU, LLC
2022–2030